ACADIA Pharmaceuticals ( NASDAQ:ACAD – Get Free Report ) ‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $41.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 76.56% from the stock’s previous close.
A number of other research firms also recently commented on ACAD. BMO Capital Markets raised their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, July 21st. Oppenheimer reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded shares of ACADIA Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, August 12th. Finally, Stifel Nicolaus lifted their price target on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a res...